For patients with acute myeloid leukemia (AML) treated with chemotherapy, the contribution of genetic heterogeneity to drug resistance and disease progression has been well-established. More recently, studies have begun to investigate the impact of transcriptional heterogeneity to tumor adaptability. However, bulk RNA-sequencing has lacked the resolution to allow the identification of canonical, relapse-associated transcriptional changes. To better understand relapse-associated clonal and transcriptional adaptation, Dr. Allegra Petti and colleagues turned to enhanced whole genome sequencing (eWGS) and ultra-deep single cell RNA-sequencing (scRNA-seq) to examine the correlation between genetic and transcriptional evolution.
Join this webinar, to hear Dr. Petti discuss the findings of this study and learn about:
How integration of eWGS and scRNA-seq enabled quantitative measurement of the co-evolution of genetic and transcriptional heterogeneity and resolved subclone-specific states
Findings indicating that clonal evolution does not represent all relevant biological changes
The identification of leukemic cells seeding resistance
Newsletters
Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.
